Who to call at Celltrion, and when
Fundz watches for the moments Celltrion starts buying, and tells you who to reach.
- An alert the day Celltrion raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Celltrion, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Celltrion. With Fundz connected, it knows.
Celltrion Secures Exclusive Supply Agreement for Omlyclo and Aptozma with U.S. Healthcare Company to Expand Market Access.
Contract Type
agreement
IncheonManufacturingBiotechnologyTherapeuticsPharmaceuticalBiopharmaDescription
Celltrion has signed a significant exclusive supply agreement with a major U.S. healthcare company for its products Omlyclo and Aptozma. This agreement will ensure that both treatments are listed as preferred drugs on the insurer's formulary, aiming to enhance accessibility and insurance reimbursement for patients.
Quick answer
Celltrion Secures Exclusive Supply Agreement for Omlyclo and Aptozma with U.S. Healthcare Company to Expand Market Access. (October 26, 2026). Celltrion is based in Incheon, Seoul, South Korea.
- What agreement did Celltrion announce on October 26, 2026?
- Celltrion has signed a significant exclusive supply agreement with a major U.S. healthcare company for its products Omlyclo and Aptozma. This agreement will ensure that both treatments are listed as preferred drugs on the insurer's formulary, aiming to enhance accessibility and insurance reimbursement for patients.
- What does Celltrion do?
- Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specialises in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives...
- Where is Celltrion based?
- Celltrion is based in Incheon, Seoul, South Korea.
- Which similar companies announced agreements around the same time?
- AbbVie Inc. (November 3, 2026), Sino Biopharmaceutical (November 13, 2026), Incyte Corporation (October 24, 2026) and Teva Pharmaceutical Industries Ltd (November 3, 2026) also announced agreements within 45 days of Celltrion.
Source: Fundz verified event record.
Other recent agreements in Therapeutics and Pharmaceutical
Contracts and agreements at companies in the same sectors within 45 days, from Fundz verified event records.
- AbbVie partners with McLaren Racing in a multiyear collaboration to promote liver health awareness through Formula 1. (November 3, 2026)
- Sino Biopharmaceutical Partners with Boehringer Ingelheim in a $358 Million Oncology Deal (November 13, 2026)
- Incyte and Genmab Form Partnership to Explore New Treatment for KRAS G12D-Mutated Metastatic Colorectal Cancer. (October 24, 2026)
- Teva and Samsung Bioepis Sign Agreement for U.S. Rights to Biosimilars Infliximab and Etanercept. (November 3, 2026)
- Edesa Biotech Enters Collaboration and License Agreement with Kyorin Pharmaceutical (November 9, 2026)
- Pfizer Partners with Blackstone Life Sciences to Co-Fund $1.5 Billion Development for Berobenatide Obesity Drug. (November 14, 2026)
Related People
Celltrion signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.